MarketPR
A $50.0 million at-the-market equity facility is in focus for Coherus Oncology (CHRS) after the Redwood City, California oncology company signed a sales agreement with Leerink Partners LLC on August 28, 2026, and filed a prospectus supplement the same day to activate it.
The arrangement draws on a Form S-3 shelf registration, File No. 333-291520, that the SEC declared effective December 8, 2025.
What to watch now is how quickly the company begins disclosing actual share sales in subsequent filings.
Terms and mechanics Under the agreement, Leerink Partners will sell shares of CHRS common stock, par value $0.0001 per share, on instructions from Coherus specifying any price, time, or size limits.
Keep reading